ERBB2 N857S

CI-VAR-00002971Explore in graph →NP_004439.2:p.Asn857SerNM_004448.3:c.2570A>GClinVar 13880 CIViC 873 rs28933370

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
ERBB2 N857S	Lapatinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1988 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-N857S showed IC50 value of 75nM and IC90 of approximately 0.5 µM, and was considered as lapatinib-sensitive. Since levels of up to 1 µM of l… (full text at CIViC) PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13880	Pathogenic	no assertion criteria provided	0	Ovarian neoplasm	somatic	1	Sep 30, 2004	clinvar